AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
damage, today announced its participation at the combined 2018
Meetings of the
American Association for Hand Surgery
(AAHS), American Society for Peripheral Nerve (ASPN), and
the
American Society for Reconstructive Microsurgery
(ASRM). The meeting will take place in Phoenix, Arizona
from January 10-16, 2018. This annual combined meeting brings
together more than 850 clinicians representing hand and plastic
surgeons to learn about emerging clinical evidence and surgical
techniques in a peer-to-peer setting.
AxoGen will host an educational symposium on Thursday, January
11, 2018 at 1:00 p.m. “Overcoming Challenges in Nerve
Repair: The Recent Evolution of the Evidence-Based
Algorithm” will focus on the rapidly growing body of
peer-reviewed literature related to peripheral nerve repair. A
faculty panel of renowned surgeons will share how they have
implemented new techniques and algorithms into their own practices.
The interactive symposium will include practical advice, supported
by clinical evidence, that can be implemented immediately.
“We are pleased with the increased number and variety of
peripheral nerve repair presentations at this scientific meeting
and believe their inclusion reflects a growing interest in the
clinical evidence supporting our platform for nerve repair,” stated
Karen Zaderej, AxoGen’s president and CEO. “It is gratifying to see
our ongoing commitment to clinical research and advancing the
science of peripheral nerve repair being recognized by these
leading professional societies.”
In addition to the company-sponsored symposium, there are
several abstracts, posters, and podium presentations related to
AxoGen products during the meeting. Bauback Safa, M.D. will present
Motor Functional Recovery after Median Nerve
Reconstructions using Processed Nerve Allografts on
Friday, January 12th during the Scientific Paper presentations. The
presentation is based on data from the AxoGen-sponsored RANGER®
registry, and includes an updated dataset for these specific mixed
and motor nerve injuries.
Also on Friday, Immediate Allograft Outcomes of Long
Span Defects of the Inferior Alveolar Nerve, authored by
David Salomon, DDS; Michael R Markiewicz, MD, DDS, MPH; and Michael
Miloro, MD, DMD, FACS, will include outcomes of long-gap nerve
repair in oral and maxillofacial cases.
Avive® Soft Tissue Membrane will be featured in a poster,
Peripheral Nerve Surgery with Processed Human Umbilical
Cord: Clinical Case Series, authored by Andrew Watt, M.D.,
Paul Sibley, M.D., Robert Hagan, M.D., Mark S. Rekant, M.D., Harry
Hoyen, M.D., and Bauback Safa, M.D.
Two presentations highlighting data from the development of
AxoGuard® Nerve Cap are also included in the meeting agenda,
Application of a Porcine SIS Nerve Cap for Prevention of
Neuromas and Associated Pain and Prevention of
Neuromas with a Porcine SIS Nerve Cap: A Histopathological
Evaluation. These pre-clinical presentations include data
on the reduction of pain and histological findings from the use of
AxoGuard® Nerve Cap for the prevention of painful or symptomatic
neuroma. The AxoGuard® Nerve Cap, which received FDA clearance last
year, may provide surgeons with a new option to protect the
peripheral nerve end and separate the nerve from the surrounding
environment to reduce the development of a symptomatic or painful
neuroma. AxoGen continues to evaluate the application of current
and new products in the surgical management of pain.
Additional panel discussions, scientific papers, and posters
related to AxoGen products and clinical studies will be presented
throughout the conference. Conference attendees can learn more
about AxoGen’s platform for nerve repair by visiting Booth #13 in
the exhibit hall.
About AAHS The American Association for Hand
Surgery represents a diverse but cohesive mix of highly respected
professionals working in all disciplines of hand surgery and hand
therapy. Members include orthopedic surgeons, plastic surgeons,
general surgeons, microsurgeons, hand therapists, nurses, and basic
scientists from the United States, Canada, and many other
countries. For more information, please visit:
www.handsurgery.org.
About ASPN The American Society for Peripheral
Nerve was established to stimulate and encourage study and research
in the field of neural regeneration, to provide a forum for the
presentation of the latest research and relevant clinical
information and to serve as a unifying authority on all areas of
neural regeneration and restorative neuroscience. For more
information, please visit: www.peripheralnerve.org.
About ASRM The American Society for
Reconstructive Microsurgery was established to promote, encourage,
foster, and advance the art and science of microsurgery and complex
reconstruction and to establish a forum for teaching, research and
free discussion of reconstructive microsurgical methods and
principles. For more information, please visit:
www.microsurg.org.
About the RANGER® StudyThe RANGER® Study, A
Multicenter Retrospective Study of Avance® Nerve Graft Utilization
Evaluations and Outcomes in Peripheral Nerve Injury Repair is an
active, multicenter clinical database designed to continuously
monitor and collect injury, repair, safety, and outcomes data for
peripheral nerve injuries repaired with processed nerve allograft
(Avance® Nerve Graft), nerve autograft, and synthetic tubes. The
study currently includes more than 1,300 nerve repairs enrolled in
more than 30 centers. The RANGER® Study is an AxoGen sponsored
ongoing open label registry study. Each patient outcome is
dependent upon the nature and extent of nerve loss or damage,
timing between nerve loss and repair and the natural course of the
patient’s recovery.
About AxoGenAxoGen (AXGN) is the leading
company focused specifically on the science, development and
commercialization of technologies for peripheral nerve regeneration
and repair. We are passionate about helping to restore nerve
function and quality of life to patients with peripheral nerve
injuries by providing innovative, clinically proven and
economically effective repair solutions for surgeons and health
care providers. Peripheral nerves provide the pathways for both
motor and sensory signals throughout the body. Every day, people
suffer traumatic injuries or undergo surgical procedures that
impact the function of their peripheral nerves. Damage to a
peripheral nerve can result in the loss of muscle or organ
function, the loss of sensory feeling, or the initiation of
pain.
AxoGen's platform for nerve repair features a comprehensive
portfolio of products, including Avance® Nerve Graft, an
off-the-shelf processed human nerve allograft for bridging severed
nerves without the comorbidities associated with a second surgical
site, AxoGuard® Nerve Connector, a porcine submucosa extracellular
matrix (ECM) coaptation aid for tensionless repair of severed
nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product
used to wrap and protect injured peripheral nerves and reinforce
the nerve reconstruction while preventing soft tissue attachments,
and Avive® Soft Tissue Membrane, a minimally processed human
umbilical cord membrane that may be used as a resorbable soft
tissue covering to separate tissue layers and modulate inflammation
in the surgical bed. Along with these core surgical products,
AxoGen also offers AcroVal® Neurosensory & Motor Testing System
and AxoTouch® Two-Point Discriminator. These evaluation and
measurement tools assist health care professionals in detecting
changes in sensation, assessing return of sensory, grip, and pinch
function, evaluating effective treatment interventions, and
providing feedback to patients on nerve function. The AxoGen
portfolio of products is available in the United States, Canada,
the United Kingdom, and several other European and international
countries.
Cautionary Statements Concerning Forward-Looking
Statements This Press Release contains "forward-looking"
statements as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations or predictions of future conditions, events, or
results based on various assumptions and management's estimates of
trends and economic factors in the markets in which we are active,
as well as our business plans. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "projects," "forecasts," "continue," "may," "should,"
"will," and variations of such words and similar expressions are
intended to identify such forward-looking statements. The
forward-looking statements may include, without limitation,
statements regarding our assessment on our internal control over
financial reporting, our growth, our 2017 and 2018 guidance,
product development, product potential, financial performance,
sales growth, product adoption, market awareness of our products,
data validation, our visibility at and sponsorship of conferences
and educational events. The forward-looking statements are subject
to risks and uncertainties, which may cause results to differ
materially from those set forth in the statements. Forward-looking
statements in this release should be evaluated together with the
many uncertainties that affect AxoGen's business and its market,
particularly those discussed in the risk factors and cautionary
statements in AxoGen's filings with the Securities and Exchange
Commission. Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made and, except as required by law, AxoGen
assumes no responsibility to update any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Contacts:AxoGen, Inc.Peter J. Mariani, Chief Financial
OfficerInvestorRelations@AxoGenInc.com
The Trout Group – Investor RelationsBrian
Korb646.378.2923bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024